Navigation Links
Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
Date:11/2/2010

BASKING RIDGE, N.J., Nov. 2, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, presented an abstract at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions on November 2, 2010 in Vancouver, BC, Canada.  The abstract is titled "Sustained Inhibition of Factor IXa by Subcutaneous RB006 with Active Reversal: First-in-Human Experience with the REG2 System."

The REG2 system is intended for use in venous thrombosis indications.  This initial Phase 1 study was the first successful subcutaneous application of an aptamer in humans.  It demonstrated that a single subcutaneous injection of RB006 (aka pegnivacogin) resulted in dose-dependent inhibition of Factor IXa with effects that persisted longer than one week after injection. The data is promising for future development of REG2.

The abstract is coauthored by Steven L. Zelenkofske, D.O., Christopher P. Rusconi, Ph.D. and Carolyn M. Darmiento, MS, all from Regado Biosciences; and Richard C. Becker, MD, Duke University School of Medicine, Durham, NC and William Wargin, Ph.D., President of PK-PM Associates, LLC.  

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market i
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015  Dr. Keesha Ewers ... potential FDA approval of flibanserin, or what is ... the treatment of decreased female sexual desire back ... root causes and addressing libido as a singular ... Photo ...
(Date:8/4/2015)... N.J. and LOS ANGELES ... Diagnostics (NYSE: DGX ), the world,s leading ... it has completed the previously announced acquisition of ... As a result of the transaction, ... extensive range of innovative services and network of ...
(Date:8/4/2015)... Calif., Aug. 4, 2015  Isis Pharmaceuticals, Inc. (Nasdaq: ... million and $18.9 million for the three and six ... net loss of $12.1 million and $43.4 million for ... results were driven primarily by the more than $90 ... related to the upfront payment from Bayer to license  ...
Breaking Medicine Technology:Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16
... Pa., May 19, 2011 ViroPharma Incorporated (Nasdaq: ... clinical study to evaluate the safety, tolerability, and efficacy of ... infection (CDI) in adults previously treated for CDI. ... study are to evaluate the safety and tolerability of VP ...
... BASKING RIDGE, N.J. and FRANKLIN LAKES, N.J., May 19, ... (NYSE: MHS ) today announced a mobile ... to the lowest-cost prescription drug to meet their health ... Available now on Verizon Wireless Android handsets and BlackBerry ...
Cached Medicine Technology:ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI) 2ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI) 3ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI) 4ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI) 5Verizon Wireless and Medco Unveil First Mobile Medication App with Real-Time Patient-Specific Drug Safety and Savings Information 2Verizon Wireless and Medco Unveil First Mobile Medication App with Real-Time Patient-Specific Drug Safety and Savings Information 3Verizon Wireless and Medco Unveil First Mobile Medication App with Real-Time Patient-Specific Drug Safety and Savings Information 4
(Date:8/5/2015)... ... 2015 , ... What language does a body speak? "Body Language – ... and other expressions that contain the name of a body part. , The use ... 2,000 such idioms, words, and expressions, for example, “back against the wall,” “brainstorming,” “sweet ...
(Date:8/5/2015)... ... , ... A leader in Primary Care Continuing Medical Education (CME), Continuing ... Barnwell as its new Director of Program Management. , Su has over 16 years ... for Primary Care Network (PCN) as the Director, Program Implementation as well as Supervisor ...
(Date:8/5/2015)... ... August 05, 2015 , ... ... clinical data standards. Members of global organisations such as PhUSE or CDISC are ... as the American FDA, the Japanese PMDA and the European EMA. A move ...
(Date:8/4/2015)... ... August 05, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. She ... nation’s leading networking organization exclusively for professional women, boasting more than 700,000 members ...
(Date:8/4/2015)... ... , ... Sponsored by Gila River Casinos, the charity event helps raise funds ... According to the New Foundation AZ spokesperson , the organization is still looking ... complimentary foursome for the tournament, as well as getting their company advertised on a ...
Breaking Medicine News(10 mins):Health News:Harvard Medical Professor Dr. Per-Olof Hasselgren Pens Unique Book Using Body Part Idioms 2Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 2Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 3Health News:Japan PMDA Publishes English Versions of Electronic Data Submission & Technical Conformance Guidance 2Health News:Japan PMDA Publishes English Versions of Electronic Data Submission & Technical Conformance Guidance 3Health News:NAPW Inducts Deborah Stevens, Executive Assistant to Chairman and CEO at Mirion Technologies, Inc., Into its VIP Woman of the Year Circle 2Health News:The New Foundation AZ to Host Charity Golf Tournament 2Health News:The New Foundation AZ to Host Charity Golf Tournament 3
... A few nonjudgmental counseling sessions can prompt women to ... contraception, according to a new study//. ,Prenatal alcohol ... and developmental disabilities in the United States. This CDC ... risk of an alcohol-exposed pregnancy. ,“A lot ...
... are trying to investigate the reason why the common ... but could make many others seriously ill. , ... carried by cats, but can also be passed on ... the disease called toxoplasmosis, which in normal circumstances is ...
... Transplant Congress, held in Boston earlier this year,// a ... transplantation were awarded the world transplant community's highest honor: ... to mark outstanding new research that will lead to ... Society, is a special issue dedicated to the World ...
... key to keeping new year’s resolutions to achieve improved health ... ,“The new year is a great time to make ... fitness,” Dr Yong said. ,“Aim to keep your ... plan to quit smoking, have a support network of friends ...
... in the U.S. over the past 50 years has declined, ... study.// ,Stroke continues to be a major public health ... in the United States. It is the third leading cause ... neurologic cause of long-term disability, according to background information in ...
... in the long run and increase the risk of hip ... the risk when// prescribing such drugs. ,Researchers ... the general practice research database of Britain. All the people ... proton pump inhibitors (PPI). ,PPI's are a ...
Cached Medicine News:Health News:Counseling Helps Young Women Cut Drinking, Improve Contraception Use 2Health News:Counseling Helps Young Women Cut Drinking, Improve Contraception Use 3Health News:Highlights from World Transplant Congress 2Health News:Highlights from World Transplant Congress 3Health News:Planning for Good Health Resolutions 2Health News:Incidence of Stroke on Decline Over Last 50 Years 2
The Easy Wrap Apron is now available with an attached Thyroid Collar. The Thyroid Collar is held on with velcro so it adjusts to fully protect the neck. This Apron with Collar is available in 5mm lea...
... StelKast's Proven™ knee system ... solution based on a clinically ... posterior stabilized and anatomically correct ... instrument standardization and ease of ...
... Oxinium (oxidized zirconium) isn't a new implant. ... Smith & Nephew. Wear debris can be ... almost nil, addressing the needs of the ... are all improved. Initially, Oxinium is available ...
The RT-PLUS Solution is an axially supported rotation knee prosthesis for cemented implantation. The implant is available in three sizes, each of which can be combined with the next size up or down....
Medicine Products: